tirzepatide type 1 diabetes trial in Adults With Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical @DiabetesCareADA 🔻 −10.3 kg in 12 weeks with tirzepatide vs −0.7 kg with placebo (P<0.0001) 🎯 100% ≥5% Tirzepatide outcompetes long-acting insulin in

Store the lyophilized product under controlled laboratory conditions to help preserve purity, stability, and performance

doi: 10.1172/JCI9259 43 FergusonJ

This assessment does not predict your exact medication response or side effect profile, but knowing your genetic predispositions can help you and your provider anticipate which tirzepatide strategies may align best with your individual physiology and optimize your injection schedule accordingly

Conclusion Due to the rise in GLP-1RA prescribing for weight loss, we recommend clinicians be vigilant regarding unremitting nausea/vomiting that occurs with lurasidone and possibly other second-generation antipsychotics upon initiation of GLP-1RAs